Effectiveness and safety of Campath-1H [alemtuzumab] as an induction agent in combination with tacrolimus monotherapy for prevention of graft rejection compared to tacrolimus in combination with MMF [mycophenolate mofetil] and steroids [corticosteroids] in cadaveric kidney transplantation

Trial Profile

Effectiveness and safety of Campath-1H [alemtuzumab] as an induction agent in combination with tacrolimus monotherapy for prevention of graft rejection compared to tacrolimus in combination with MMF [mycophenolate mofetil] and steroids [corticosteroids] in cadaveric kidney transplantation

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jun 2012

At a glance

  • Drugs Alemtuzumab (Primary) ; Corticosteroids; Methylprednisolone; Mycophenolate mofetil; Prednisolone; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jun 2012 Actual patient number changed from 131 to 197 as reported by ClinicalTrials.gov.
    • 09 May 2007 Status change from in progress to completed.
    • 23 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top